首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1517641

脂質奈米顆粒原料市場- 副產品（試劑盒[可電離、聚乙二醇化和甾醇脂質]試劑）、應用（治療、研究）、適應症（癌症、傳染病、血液疾病）、最終用途- 全球預測（2024 - 2032））

Lipid Nanoparticle Raw Materials Market - By Product (Kits [Ionizable, PEGylated, & Sterol Lipids] Reagents), Application (Therapeutics, Research), Indication (Cancer, Infectious Diseases, Blood Diseases), End-use - Global Forecast (2024 - 2032)

出版日期: 2024年04月29日 | 出版商:

Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在製藥和生物技術領域不斷擴大的應用的推動下，脂質奈米顆粒原料市場規模預計在 2024 年至 2032 年間複合年成長率為 5.7%。脂質奈米粒子 (LNP) 作為 mRNA 疫苗的有效遞送系統而受到廣泛關注。這導致該技術在其他治療領域的投資和研究增加，包括基因治療、癌症治療和罕見疾病。

對個人化醫療和精準治療的興趣日益濃厚也將影響市場的成長。 LNP 提供了一個多功能平台，可提供具有客製化特性的各種治療方法，使其成為客製化治療方案的理想選擇。慢性病的日益普及和對創新治療解決方案的需求刺激了對脂質為基礎的藥物傳遞系統的研究。根據世界衛生組織的數據，慢性病每年導致 4,100 萬人死亡，佔全球死亡人數的 74%。不斷增加的政府資金和支持性監管框架也鼓勵創新並確保高品質原料的供應，從而促進市場成長。

整個產業分為產品、適應症、應用、最終用途和地區。

從產品來看，由於脂質奈米顆粒的合成和配方，試劑領域的脂質奈米顆粒原料市場預計到 2032 年將大幅成長。脂質、溶劑和穩定劑等試劑對於製備具有精確特性的 LNP 至關重要，以適應有效的藥物傳遞。用於各種治療應用（包括 mRNA 疫苗和基因療法）的 LNP 配方的複雜性和特異性日益增加，也將推動對高品質、可靠試劑的需求。

由於奈米技術和藥物傳輸系統的不斷進步和創新，研究領域的脂質奈米顆粒原料市場預計到 2032 年將錄得可觀的成長率。深入的研究工作集中在最佳化脂質奈米顆粒的特性和功能，用於各種治療應用，包括標靶藥物傳遞、基因治療和疫苗開發。

由於製藥和生物技術產業的不斷擴大，以及政府對醫療保健基礎設施和研究投資的支持，預計亞太地區脂質奈米顆粒原料產業規模將在 2024 年至 2032 年期間大幅成長。大量熟練的研究人員和科學家的存在，加上具有成本效益的製造能力，正在加強亞太地區脂質奈米顆粒技術的開發和生產。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病盛行率增加
  - 藥物傳輸技術的進步
  - 政府支持和資助
  - 生醫產業快速擴張
- 產業陷阱與挑戰
  - 嚴格的監管場景
  - 開發成本高
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
套件
- 可電離脂質
- 聚乙二醇化脂質
- 固醇脂質
- 中性磷脂
試劑
其他產品

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
療法
研究

第 7 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
癌症
傳染性疾病
血液疾病
其他適應症

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
製藥和生物技術公司
學術及研究機構
其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 荷蘭
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Biopharma PEG Scientific Inc.
BroadPharm
CordenPharma
Creative Biolabs.
Croda International Plc
Echelon Biosciences
Merck KGaA
NOF Corporation
Polysciences, Inc.
Tebubio

簡介目錄

Product Code: 9266

Lipid nanoparticle raw materials market size is estimated to register 5.7% CAGR between 2024 and 2032, driven by expanding applications in pharmaceutical and biotechnology sectors. Lipid nanoparticles (LNPs) have gained significant attention as effective delivery systems for mRNA vaccines. This has led to increased investments and research in this technology for other therapeutic areas, including gene therapy, cancer treatment, and rare diseases.

The rising interest in personalized medicine and precision therapeutics will also influence the market growth. LNPs offer a versatile platform for delivering a wide range of therapeutics with tailored properties, making them ideal for customized treatment regimens. The increasing prevalence of chronic diseases and the need for innovative treatment solutions have spurred research into lipid-based drug delivery systems. As per WHO, chronic diseases cause 41 million deaths annually, accounting for 74% of all global fatalities. The rising government funding and supportive regulatory frameworks are also encouraging innovations and ensuring the availability of high-quality raw materials, adding to the market growth.

The overall industry is classified into product, indication, application, end-use and region.

Based on product, the lipid nanoparticle raw materials market from the reagents segment is predicted to witness substantial growth rate through 2032 due to the synthesis and formulation of lipid nanoparticles. Reagents, such as lipids, solvents, and stabilizers are essential for creating LNPs with precise characteristics to cater to effective drug delivery. The increasing complexity and specificity of LNP formulations for various therapeutic applications, including mRNA vaccines and gene therapies, will also drive the demand for high-quality, reliable reagents.

Lipid nanoparticle raw materials market from the research segment is predicted to record decent growth rate through 2032, owing to the continuous advancements and innovations in nanotechnology and drug delivery systems. Intensive research efforts are focused on optimizing the properties and functionalities of lipid nanoparticles for various therapeutic applications, including targeted drug delivery, gene therapy, and vaccine development.

Asia Pacific lipid nanoparticles raw materials industry size is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding pharmaceutical and biotechnology industries, supported by government investments in healthcare infrastructure and research. The presence of a large pool of skilled researchers and scientists, coupled with cost-effective manufacturing capabilities, is enhancing the development and production of lipid nanoparticle technologies in APAC.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Advancements in drug delivery technologies
  - 3.2.1.3 Government support and funding
  - 3.2.1.4 Rapid expansion of the biopharmaceutical industry
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High development costs
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Kits
- 5.2.1 Ionizable lipids
- 5.2.2 PEGylated lipids
- 5.2.3 Sterol lipids
- 5.2.4 Neutral phospholipids
5.3 Reagents
5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Therapeutics
6.3 Research

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Infectious diseases
7.4 Blood diseases
7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical & biotechnology companies
8.3 Academic & research institutes
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Netherlands
- 9.3.6 Italy
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa